HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival

Human Pathology

Volumn 48, Issue , 2016, Pages 95-101

  Davidson, Ben ^a,b   Holth, Arild ^a   Hellesylt, Ellen ^a   Hadar, Rivka ^c   Katz, Betina ^a   Tropé, Claes G ^a,b   Reich, Reuven ^c,d  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Effusion; High grade serous carcinoma; HuR; Immunohistochemistry; Reverse transcription polymerase chain reaction; Survival

Indexed keywords

CA 125 ANTIGEN; ELAV LIKE PROTEIN 1; MESSENGER RNA; SMALL INTERFERING RNA; ELAVL1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; EFFUSION; FEMALE; GENE; GENE EXPRESSION; GENE FUNCTION; HIGH GRADE OVARIAN SEROUS CARCINOMA; HUMAN; HUMAN TISSUE; HUR GENE; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SPACE; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; BIOSYNTHESIS; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; GENETIC TRANSFECTION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; VERY ELDERLY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ELAV-LIKE PROTEIN 1; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; YOUNG ADULT;

EID: 84954403085     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.09.027     Document Type: Article

References (20)

1. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics, 2014 CA Cancer J Clin 64 2014 9 29
2. B. Davidson, R. Reich, C.G. Trope', T.L. Wang, and IeM Shih New determinates of disease progression and outcome in metastatic ovarian carcinoma Histol Histopathol 25 2010 1591 1609
3. B. Davidson, P. Firat, and C.W. Michael Serous Effusions 2011 Springer London, UK
4. L. Wurth, and F. Gebauer RNA-binding proteins, multifaceted translational regulators in cancer Biochim Biophys Acta 2015 1849 881 886
5. I. Kotta-Loizou, C. Giaginis, and S. Theocharis Clinical significance of HuR expression in human malignancy Med Oncol 31 2014 161
6. J. Wang, Y. Guo, H. Chu, Y. Guan, J. Bi, and B. Wang Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis Int J Mol Sci 14 2013 10015 10041
7. Z. Lu, R.Z. Luo, H. Peng, and et al. Transcriptional and posttranscriptional down-regulation of the imprinted tumor suppressor gene ARHI (DRAS3) in ovarian cancer Clin Cancer Res 12 2006 2404 2413
8. G. Raspaglio, I. De Maria, F. Filippetti, and et al. HuR regulates beta-tubulin isotype expression in ovarian cancer Cancer Res 70 2010 5891 5900
9. S. Prislei, E. Martinelli, M. Mariani, and et al. MiR-200c and HuR in ovarian cancer BMC Cancer 13 2013 72
10. T.L. Erkinheimo, H. Lassus, A. Sivula, and et al. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma Cancer Res 63 2003 7591 7594
11. R.A. Oyesanya, Z.P. Lee, J. Wu, and et al. Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells FASEB J 22 2008 2639 2651
12. K. Abdelmohsen, S. Srikantan, Y. Kuwano, and M. Gorospe miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels Proc Natl Acad Sci U S A 105 2008 20297 20302
13. X. Yi, Y. Zhou, W. Zheng, and S.K. Chambers HuR expression in the nucleus correlates with high histological grade and poor disease-free survival in ovarian cancer Aust N Z J Obstet Gynaecol 49 2009 93 98
14. C. Denkert, W. Weichert, S. Pest, and et al. Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression Cancer Res 64 2004 189 195
15. J.T. Thigpen, J.A. Blessing, H. Ball, and et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study J Clin Oncol 12 1994 1748 1753
16. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, and et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
17. T.E. Hetland, E. Hellesylt, V.A. Flørenes, C.G. Tropé, B. Davidson, and J. Kærn Class III beta-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance Hum Pathol 42 2011 1019 1026
18. V. Vaksman, C. Tropé, B. Davidson, and R. Reich Exosome-derived miRNAs and ovarian carcinoma progression Carcinogenesis 35 2014 2113 2120
19. 2 isoforms in advanced-stage ovarian carcinoma Gynecol Oncol 103 2006 831 840
20. B. Davidson, Y.B. Rosenfeld, C.G. Tropé, R. Reich, and J. Yisraeli VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival Hum Pathol 45 2014 1520 1528